Figure 1 Patient, facility, health-care system and industry factors

Slides:

Advertisements

Similar presentations

Nat. Rev. Cardiol. doi: /nrcardio

Advertisements

Nat. Rev. Nephrol. doi: /nrneph

Figure 3 Life expectancy at birth in all countries included

Nat. Rev. Nephrol. doi: /nrneph

Figure 5 A layered approach to the follow-up of patients with acute kidney disease (AKD) Figure 5 | A layered approach to the follow-up of patients with.

Figure 4 Interplay between acute kidney injury (AKI),

Figure 6 Effects of adiponectin on podocyte function

Figure 5 Inter-relationships between sleep apnoea, CKD and brain injury Figure 5 | Inter-relationships between sleep apnoea, CKD and brain injury. In chronic.

Figure 6 Differences in glycaemic control with the study drug

Figure 6 Approach to drug management in patients with acute kidney disease (AKD) Figure 6 | Approach to drug management in patients with acute kidney disease.

Among Medicare beneficiaries >65 years old with a index hospitalization at the time of dialysis initiation, use of post-acute SNF care was common. Among.

Figure 4 Interactions between adipose, the microbiome and kidney

Nat. Rev. Nephrol. doi: /nrneph

Figure 1 Mechanisms of kidney injury in the setting of obesity

Nat. Rev. Endocrinol. doi: /nrendo

Figure 2 Physiological changes in the renal system in pregnancy

Nat. Rev. Nephrol. doi: /nrneph

Figure 1 Model of mechanosensation through primary cilia

Nat. Rev. Nephrol. doi: /nrneph

Nat. Rev. Nephrol. doi: /nrneph

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Nephrol. doi: /nrneph

Nat. Rev. Cardiol. doi: /nrcardio

Figure 6 The bioavailability of phosphate differs according to the protein source Figure 6 | The bioavailability of phosphate differs according to the.

Figure 7 The efficacy of phosphate-binder therapy

Figure 3 Putative actions of glucagon-like peptide 1 (GLP-1)

Nat. Rev. Urol. doi: /nrurol

Figure 2 Expression of complement activation products in renal samples

Figure 5 Risk factor control in the intensive treatment group

Figure 2 The network of chronic diseases and their mutual influences

Figure 1 The burden of chronic kidney disease (CKD)

Figure 3 Societal costs for the care of patients with chronic kidney disease in the UK Figure 3 | Societal costs for the care of patients with chronic.

Figure 2 Glomerular pathology in mice and humans with diabetic nephropathy Figure 2 | Glomerular pathology in mice and humans with diabetic nephropathy.

Figure 2 Podocyte dysfunction is a common feature of renal injury

Figure 1 Sequential impact of diabetes platforms, genetic backgrounds and accelerators on albuminuria and kidney pathology in mouse models of diabetic.

Figure 1 Acute kidney injury and chronic kidney disease

Figure 4 The gut–kidney axis, inflammation and cardiovascular disease in CKD Figure 4 | The gut–kidney axis, inflammation and cardiovascular disease in.

Figure 2 The continuum of acute kidney injury (AKI),

Figure 4 Model of changes in the serum levels

Nat. Rev. Nephrol. doi: /nrneph

Figure 1 Health-care system today

Figure 2 Endocrine dysfunction in mitochondrial disease and their associated gene defects Figure 2 | Endocrine dysfunction in mitochondrial disease and.

Figure 1 Cardiovascular risk and disease across the life-course

Nat. Rev. Nephrol. doi: /nrneph

Figure 1 Changes in relative plasma volume (RPV)

Figure 2 Global cost of HF per capita in 2012

Nat. Rev. Cardiol. doi: /nrcardio

Figure 4 The molecular configuration of the CD20 molecule

Nat. Rev. Nephrol. doi: /nrneph

Nat. Rev. Nephrol. doi: /nrneph

Nat. Rev. Nephrol. doi: /nrneph

Nat. Rev. Nephrol. doi: /nrneph

Figure 3 Challenges for big data applications in cardiovascular care

Figure 3 Hypothetical trajectories of acute kidney disease (AKD)

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Nephrol. doi: /nrneph

Figure 3 Serum phosphate level is associated with

Nat. Rev. Nephrol. doi: /nrneph

Figure 3 Regulation of TGF-β1/Smad signalling by microRNAs (miRs) in tissue fibrosis Figure 3 | Regulation of TGF-β1/Smad signalling by microRNAs (miRs)

Figure 1 The relationship between health fitness and pathogen load

Nat. Rev. Nephrol. doi: /nrneph

Nat. Rev. Nephrol. doi: /nrneph

Nat. Rev. Cardiol. doi: /nrcardio

Figure 4 Intracellular distribution and

Figure 1 Overall worldwide prevalence ranges for SLE

Figure 1 Worldwide distribution of disease burden attributable to environmental risks in 2012 Figure 1 | Worldwide distribution of disease burden attributable.

Figure 1 Worldwide prevalence of MRSA

Nat. Rev. Nephrol. doi: /nrneph

Organization as an Enabler of High Performance

Figure 1 Relationships between genetic variants, quantitative traits and diseases Figure 1 | Relationships between genetic variants, quantitative traits.

Presentation transcript:

Figure 1 Patient, facility, health-care system and industry factors that can influence the recruitment and retention of patients on peritoneal dialysis Figure 1 | Patient, facility, health-care system and industry factors that can influence the recruitment and retention of patients on peritoneal dialysis. Examples from Thailand, the USA, Hong Kong, China and Oceania demonstrate the importance of health-care system factors in facilitating use of peritoneal dialysis. Facility factors have a particularly important impact on the uptake of peritoneal dialysis in many African countries. Li, P. K.-T. et al. (2016) Changes in the worldwide epidemiology of peritoneal dialysis Nat. Rev. Nephrol. doi:10.1038/nrneph.2016.181